- Home
- SBMT vs NYXH Comparison
SBMT vs NYXH Comparison
Compare SBMT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBMT | NYXH |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 137.5M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBMT | NYXH |
|---|---|---|
| Price | $7.35 | $1.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $20.13 | $4.20 |
| AVG Volume (30 Days) | 82.6K | ★ 151.4K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | N/A | $93.27 |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $1.26 |
| 52 Week High | $9.48 | $6.20 |
Technical Indicators
Market Signals| Indicator | SBMT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 40.58 |
| Support Level | $7.27 | $1.28 |
| Resistance Level | $7.80 | $1.69 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 3.39 | 7.50 |
Price Performance
Historical ComparisonAbout SBMT Silver Bow Mining Corp. Common Shares
Silver Bow Mining Corp is engaged in the acquisition, exploration, and development of mineral resource properties in Butte, Montana, USA. The Company's primary business objective is to identify and evaluate prospective properties with the potential for future extraction and commercialization.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.